目的 觀察前列地爾聯合低分子肝素治療不穩(wěn)定型心絞痛（UAP）患者的臨床療效和不良反應。方法 78例UAP患者按治療方法分為對照組和治療組，每組39例。對照組給予低分子肝素鈉治療，同時給予阿司匹林和硝酸甘油等常規(guī)治療，治療組在對照組基礎上聯合應用前列地爾治療，均治療14 d。比較兩組治療前后心絞痛發(fā)作次數、持續(xù)時間、心電圖改變及不良反應的發(fā)生情況。結果 經14 d治療后，治療組患者心絞痛發(fā)作次數和持續(xù)時間均低于對照組，差異有統(tǒng)計學意義（P<0.05）。治療組心電圖改善情況優(yōu)于對照組，差異有統(tǒng)計學意義（P<0.05）。治療組的總有效率（94.87%）大于對照組（76.92%），差異有統(tǒng)計學意義（P<0.05）。治療期間兩組患者均未出現明顯的不良反應。結論 在低分子肝素鈉常規(guī)治療基礎上聯合應用前列地爾對不穩(wěn)定型心絞痛具有顯著療效。

Objective To observe the clinical efficacy and adverse reactions of low molecular heparin combined with alprostadil in the treatment of unstable angina (UAP) patients. Methods 78 patients with UAP were divided into control group and treatment group by treatment methods, with 39 cases in each group. The control group was treated with low molecular weight heparin sodium and conventional treatment such as aspirin and nitroglycerin. The treatment group was treated with alproterol on the basis of the control group and both groups treated with 14 days. The incidence of angina pectoris, duration, ECG changes and adverse reactions were compared between the two groups before and after treatment. Results After treatment, the number of angina and duration of angina in the treatment group were lower than that in the control group, and the difference was statistically significant (P < 0.05). The improvement of electrocardiogram was better than the control group, and the difference was statistically significant (P < 0.05). The total effective rate of treatment group (94.87%) was better than that of the control group (76.92%), and the difference was statistically significant (P < 0.05). No obvious adverse reactions were observed between the two groups during the treatment. Conclusions The combined application of alprosite in the conventional treatment of low molecular heparin sodium has significant effect on unstable angina pectoris.

國家自然青年基金項目（81500323）